---
title: "Reviews — xenadrine - Flapen"
canonical_url: "https://flapen.com/research/us/health-household/xenadrine/reviews"
last_updated: "2026-08-09T21:46:49.417Z"
locale: en
meta:
  description: "Niche score 62/100 · $2.3M/yr market. A failed launch gate (market size, growth, or returns) keeps it on the watch list. Data updated Jul 2026."
  "og:description": "Niche score 62/100 · $2.3M/yr market. A failed launch gate (market size, growth, or returns) keeps it on the watch list. Data updated Jul 2026."
  "og:title": "Reviews — xenadrine - Flapen"
---

# **xenadrine**

**Worth a look**

Shows low returns (0.0%), but a failed launch gate (market size, growth, or returns) keeps it on the watch list.

Market size 95Growth 22Conversion 86Competition 38Returns 100Price range 95Avg price 95Brand share 0Review moat 24Quality gap 88

**Returns**

**Incredible****0.0%**

return rate — above 5% kills the launch gate

**Market size**

**Incredible****$2.3M**

$2.3M/yr · 952K searches

**Avg price**

**Incredible****$25.32**

avg listing price — sweet spot $15–$100

**Price range**

**Incredible****$19.64–$40.50**

cheapest to priciest tracked listing — scored on the share inside $15–$100

**Quality gap**

**Great****4.1★**

avg incumbent rating — lower means beatable quality

**Conversion**

**Great****9.7%**

search→purchase rate — share of searches ending in a sale

**Competition**

**Okay****62%**

top-5 click share — leaders hold, buyers still browse

**Review moat**

**Bad****5,192.63**

avg incumbent reviews — the moat a new listing must climb

**Growth**

**Bad****-5.6%**

90-day search growth — must beat 0% to launch

**Brand share**

**Bad****100%**

top-5 brand share — brand-locked demand

## Reviews